GlassScriptPhysician profile
James K Bennett
NPI 1821096207
$92,827.96
in general payments reported to CMS, 2019-2025
35 companies · $31K in 2025
The $31K reported for 2025 was more than what 97% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,688 · 2020: $899 · 2021: $1,140 · 2022: $1,675 · 2023: $26K · 2024: $31K · 2025: $31K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $85K · Food and Beverage: $2,842.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $84,583.34 |
| Food and Beverage | $2,842.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $84,858.92 | 2021-2025 | Nanoknife, Nanoknife |
| Procept Biorobotics Corporation | $1,577.20 | 2019-2025 | Aquabeam Robotic System |
| Boston Scientific Corporation | $1,126.67 | 2019-2025 | Ams 700, General - Erectile Dysfunction, Greenlight Xps |
| Blue Earth Diagnostics | $657.25 | 2019-2024 | |
| Endo Pharmaceuticals INC. | $619.45 | 2019-2024 | Xiaflex, Aveed |
| Janssen Biotech, INC. | $520.35 | 2019-2025 | Erleada, Akeega |
| Astellas Pharma US INC | $428.03 | 2019-2025 | Xtandi |
| Medtronic, INC. | $393.95 | 2021-2025 | Interstim, Altaviva |
| Myriad Genetic Laboratories, INC. | $377.97 | 2020-2025 | Myrisk |
| Axonics, INC. | $360.16 | 2020-2023 | Axonics |
| Myovant Sciences INC. | $200.61 | 2021-2022 | |
| Abbvie INC. | $193.59 | 2019-2023 | Lupron Depot |
| Rochester Medical Corporation | $190.68 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $177.31 | 2023-2025 | Orgovyx, Gemtesa |
| Ethicon US, LLC | $176.14 | 2019 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dendreon Pharmaceuticals LLC | $161.97 | 2019-2020 | |
| Pfizer INC. | $121.35 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $121.10 | 2020-2023 | Lynparza |
| Verity Pharmaceuticals INC. | $111.76 | 2023-2025 | Trelstar |
| Acerus Pharmaceuticals Corporation | $76.80 | 2021 | |
| Palette Life Sciences, INC. | $45.81 | 2022 | |
| Abc Home Medical Supply, INC. | $45.63 | 2022-2023 | |
| Endo USA, INC. | $43.49 | 2024 | Xiaflex, Aveed |
| Bioprotect Medical, INC. | $31.28 | 2024-2025 | Bioprotect Balloon Implant System |
| Clarus Therapeutics INC. | $31.15 | 2021 | |
| Teleflex LLC | $27.73 | 2024 | |
| Tolmar, INC. | $25.51 | 2023 | |
| Novartis Pharmaceuticals Corporation | $23.54 | 2019 | |
| Accord Healthcare, INC. | $22.92 | 2024 | |
| Progenics Pharmaceuticals, INC. | $15.90 | 2022 | |
| Metuchen Pharmaceuticals | $13.81 | 2019 | |
| Medtronic USA, INC. | $13.61 | 2020 | |
| Ferring Pharmaceuticals INC. | $12.49 | 2019 | |
| Laborie Medical Technologies Corp. | $12.29 | 2020 | |
| Coloplast Corp | $11.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Bennett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.